Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3CHRM1CHRM2CHRM3CHRM4ESR1ESR2GABRA1GABRB1GABRG2GBA1HRH1HTR1DHTR2AOPRD1OPRK1OPRM1SLC6A2SLC6A3TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cadaverine Tartrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE2 | O96020 | 20/20 | 0.69 |
| ▸ | CCNE1 | P24864 | 20/20 | 0.69 |
| ▸ | CDK2 | P24941 | 20/20 | 0.69 |
| ▸ | CCNA2 | P20248 | 19/20 | 0.69 |
| ▸ | CCNA1 | P78396 | 19/20 | 0.69 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.61 |
| ▸ | CDK1 | P06493 | 1/20 | 0.61 |
| ▸ | CDK4 | P11802 | 1/20 | 0.61 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.61 |
| ▸ | CCND1 | P24385 | 1/20 | 0.61 |
| ▸ | FLT3 | P36888 | 1/20 | 0.61 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cadaverine Tartrate SCHEMBL5629659 | 0.94 | CCNE2 (0.66) | CCNE2CCNE1CDK2CCNA2CCNA1 | |
| SCHEMBL5195310 | 0.93 | CCNE2 (0.77) | CCNE2CCNE1CDK2CCNA2CCNA1 | |
| SCHEMBL5196149 | 0.93 | CCNE2 (0.77) | CCNE2CCNE1CDK2CCNA2CCNA1 | |
| SCHEMBL5195563 | 0.86 | CCNE2 (0.75) | CCNE2CCNE1CDK2CCNA2CCNA1 | |
| SCHEMBL5195558 | 0.86 | CCNE2 (0.75) | CCNE2CCNE1CDK2CCNA2CCNA1 | |
| SCHEMBL6821203 | 0.86 | CCNE2 (0.90) | CCNE2CCNE1CDK2CCNA2CCNA1 | |
| SCHEMBL6821200 | 0.86 | CCNE2 (0.90) | CCNE2CCNE1CDK2CCNA2CCNA1 | |
| Hydrochloric Acid SCHEMBL6820812 | 0.85 | CCNE2 (0.88) | CCNE2CCNE1CDK2CCNA2CCNA1 | |
| Hydrochloric Acid SCHEMBL6824017 | 0.85 | CCNE2 (0.88) | CCNE2CCNE1CDK2CCNA2CCNA1 | |
| Hydrochloric Acid SCHEMBL6820813 | 0.85 | CCNE2 (0.88) | CCNE2CCNE1CDK2CCNA2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7208598-B2 | Derivatives of purine, their preparation process and pharmaceutical compositions containing them | AVENTIS PHARMA (FR) | 2007-04-24 | — | — | US | disclosed |
| US-7122669-B1 | Purine derivatives, preparation method and pharmaceutical compositions containing same | HOECHST MARION ROUSSEL (FR) | 2006-10-17 | — | — | US | disclosed |
| US-20050187228-A1 | Derivatives of purine, their preparation process and pharmaceutical compositions containing them | AVENTIS PHARMA S.A. | 2005-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050187228-A1 | Derivatives of purine, their preparation process and pharmaceutical compositions containing them | CDK6, CDK1, CDK2 | CCNE2 34/4885CCNE1 4/4885CDK2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.